An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232-104 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML)

Project: Research

Project Details

Project Description

NMA HREC Reference Number: 65293
NMA SSA Reference Number: SSA/65293/MonH-2020-234837(v2)
Monash Health Reference: RES-20-0000-433A
StatusActive
Effective start/end date8/09/20 → 7/09/25
View all
View less

Keywords

  • clinical trial
  • phase 1 and 2 study
  • treatment safety
  • treatment efficacy
  • leukemia